🔗 Visit the ClinicalTrials.gov page for NCT01708941
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. | J Leukoc Biol | 2013 | 1.90 |
| 2 | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. | Oncoimmunology | 2014 | 1.22 |
| 3 | Immune checkpoint inhibitors in clinical trials. | Chin J Cancer | 2014 | 0.98 |
| 4 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. | Curr Oncol Rep | 2013 | 0.94 |
| 5 | Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. | Hum Vaccin Immunother | 2016 | 0.75 |